For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | - | 0 | 0 | 705 |
| Research and development | 537,674 | 150,777 | 59,471 | 51,999 |
| Acquired in-process research and development | 0 | 15,007 | - | - |
| General and administrative | 556,750 | 60,527 | 30,265 | 26,743 |
| In-process research and development | - | - | 520,915 | - |
| Impairment of intangible assets | - | 0 | 0 | 8,468 |
| Total operating expenses | 1,094,424 | 226,311 | 610,651 | 87,210 |
| Other operating income | - | - | - | 14,416 |
| Other operating income, net | - | 313 | 1,001 | - |
| Operating loss | - | -225,998 | -609,650 | -72,089 |
| Other income, net | 14,838 | 13,369 | -5,278 | -6,693 |
| Loss before income tax | - | - | -614,928 | -78,782 |
| Interest expense | 0 | 8,686 | - | - |
| Net loss | -1,079,586 | -221,315 | -614,928 | -78,782 |
| Foreign currency translation adjustments | -327 | 60 | -172 | - |
| Reclassification of unrealized loss on short-term investments to other income, net | 0 | 3 | - | - |
| Reclassification of cumulative currency translation gain to other income, net | 0 | 0 | 419 | - |
| Foreign currency translation adjustments | - | - | - | 304 |
| Unrealized gain on short-term investments | 72 | 100 | 36 | - |
| Comprehensive loss | -1,079,841 | -221,152 | -615,483 | -78,478 |
| Basic EPS | -1.44 | -0.31 | -0.99 | -0.41 |
| Diluted EPS | -1.44 | -0.31 | -0.99 | -0.41 |
| Basic Average Shares | 747,702,265 | 718,541,896 | 619,646,180 | 193,336,063 |
| Diluted Average Shares | 747,702,265 | 718,541,896 | 619,646,180 | 193,336,063 |
Summit Therapeutics Inc. (SMMT)
Summit Therapeutics Inc. (SMMT)